AZD0095|cas:2750001-23-9|西域试剂

AZD0095,99.59%

产品编号：Bellancom-148517| CAS NO：2750001-23-9| 分子式：C₂₇H₃₂N₈O₂| 分子量：500.60

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-148517	￥2800.00	杭州北京（现货）
Bellancom-148517	￥4500.00	杭州北京（现货）
Bellancom-148517	￥7000.00	杭州北京（现货）
Bellancom-148517	￥12200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

AZD0095

产品介绍

AZD0095 是一种具有选择性和口服活性的 MCT4 抑制剂 (IC₅₀: 1.3 nM)。 AZD0095 与 Cediranib (HY-10205) 联合使用可有效抑制 NCI-H358 移植瘤的肿瘤生长。

生物活性

AZD0095 is a selective and orally active MCT4 inhibitor (IC₅₀: 1.3 nM). AZD0095 effectively inhibits the tumor growth in NCI-H358 xenograft in combination with Cediranib (HY-10205).

体外研究

AZD0095 (0-50 µM) 抑制 NCI-H358 细胞 (MCT4 高表达) 的增殖，IC₅₀ 为 26 nM。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

AZD0095 (100 mg/kg, 口服，一天两次) 与 Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine NCI-H358 xenograft
Dosage:	100 mg/kg together with Cediranib (3 mg/kg)
Administration:	Oral administration (p.o.)
Result:	Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.

体内研究

AZD0095 (100 mg/kg, 口服，一天两次) 与 Cediranib (HY-10205) 联合使用抑制小鼠 NCI-H358 异种移植肿瘤的生长。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine NCI-H358 xenograft
Dosage:	100 mg/kg together with Cediranib (3 mg/kg)
Administration:	Oral administration (p.o.)
Result:	Reduced tumor growth more efficiently than AZD0095 or AZD2171 alone.